

Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/OD9C53A710D6EN.html>

Date: October 2021

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: OD9C53A710D6EN

Abstracts

Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oxurion NV (Oxurion), formerly ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company's ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion's product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements with companies such as BioInvent International, Quintiles Outcome Sciences, Bicycle Therapeutics, Galapagos, Parexel, INC Research, Grifols Inc, Patheon, and Alcon. It has a presence in Belgium, Ireland, and the US. Oxurion is headquartered in Leuven, Flemish Brabant, Belgium.

Oxurion NV Key Recent Developments

Aug 05,2021: OXURION to Participate in Upcoming Investor Meetings

May 17,2021: OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer

Apr 30,2021: OXURION presenting scientific data at ARVO 2021 Annual Meeting

Mar 31,2021: OXURION to Participate in Upcoming Investor Meetings

Feb 23,2021: H.C. Wainwright Global Life Sciences Conference (Virtual)

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

- Oxurion NV - Key Facts
- Oxurion NV - Key Employees
- Oxurion NV - Key Employee Biographies
- Oxurion NV - Major Products and Services
- Oxurion NV - History
- Oxurion NV - Company Statement
- Oxurion NV - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

- Company Overview
- Oxurion NV - Business Description
- Other Break-up: Income from Royalties
- Performance
- Other Break-up: Sales
- Performance
- Oxurion NV - Corporate Strategy
- Oxurion NV - SWOT Analysis
- SWOT Analysis - Overview
- Oxurion NV - Strengths
- Oxurion NV - Weaknesses
- Oxurion NV - Opportunities
- Oxurion NV - Threats
- Oxurion NV - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Oxurion NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Oxurion NV, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 05, 2021: OXURION to Participate in Upcoming Investor Meetings

May 17, 2021: OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer

Apr 30, 2021: OXURION presenting scientific data at ARVO 2021 Annual Meeting

Mar 31, 2021: OXURION to Participate in Upcoming Investor Meetings

Feb 23, 2021: H.C. Wainwright Global Life Sciences Conference (Virtual)

Jan 20, 2021: Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer

Oct 15, 2020: Oxurion business update – Q3 2020

Oct 13, 2020: Oxurion appoints Tom Graney, CFA as chief financial officer

Oct 05, 2020: Oxurion to host Virtual R&D Investor Day on 15 October 2020

Sep 20, 2020: Oxurion: Interim Financial Report Half-year results as at June 30, 2020

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Oxurion NV, Key Facts
Oxurion NV, Key Employees
Oxurion NV, Key Employee Biographies
Oxurion NV, Major Products and Services
Oxurion NV, History
Oxurion NV, Other Locations
Oxurion NV, Subsidiaries
Oxurion NV, Key Competitors
Oxurion NV, Ratios based on current share price
Oxurion NV, Annual Ratios
Oxurion NV, Annual Ratios (Cont...1)
Oxurion NV, Annual Ratios (Cont...2)
Oxurion NV, Interim Ratios
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oxurion NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Oxurion NV, Performance Chart (2016 - 2020)

Oxurion NV, Ratio Charts

Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/OD9C53A710D6EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OD9C53A710D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970